Biogen, Sage

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
No deal: Sage rejects Biogen's buyout offer, scouts for strategic alternatives
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. | The company's board of directors unanimously rejected partner Biogen's $469 million buyout proposal,
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
The proposal sought to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share, a valuation deemed insufficient by the Board. Meanwhile, Sage remains committed to its mission of making ZURZUVAE the standard treatment for women with postpartum depression as the Board evaluates potential strategic opportunities.
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE. Per Sage Therapeutics,
Sage Therapeutics rejects Biogen bid, starts strategic review
Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of opportunities, including a potential strategic transaction,
Sage Group’s Strong Financial Performance and Positive Growth Outlook in 2025
In a report released today, Charles Brennan from Jefferies maintained a Buy rating on Sage Group plc (SGE – Research Report), with a price ...
Sage Group rises Tuesday, still underperforms market
Sage Group PLC closed 1.08% below its 52-week high of £13.42, which the company achieved on January 22nd.
UK Software Firm Sage Maintains Annual Forecasts After Revenue Jumps
(Reuters) - Britain's Sage Group on Thursday maintained its annual revenue forecasts after the software firm posted a 10% rise in underlying revenue for the first quarter, buoyed by higher demand, ...
Sage Therapeutics price target raised to $9 from $6 at Mizuho
Mizuho raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $6 and keeps a Neutral rating on the shares. The firm reassessed ...
ITWeb on MSN7h
Sage 300 still a cornerstone for accounting, says Peresoft ahead of TPAC 2025
Sage 300 remains a cornerstone for enterprise management and accounting, says Peresoft ahead of the annual gathering of the ...
Lyon coach Pierre Sage has been fired despite putting the French league club back on track
Lyon coach Pierre Sage has been fired despite leading the French league club out of a crisis last season and having the team ...
Cloud uptake helps Sage revenues to climb 10% in first quarter
The Tyneside-based FTSE100 firm issued first quarter trading results for the three months to the end of December which showed ...
Sage Group 1Q Underlying Total Rev GBP612M
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...